Table 1.
Baseline clinical characteristic, lipid concentrations in the study groups
| Variable | ACS (n = 88) |
SCAD (n = 79) |
Control (n = 85) |
|---|---|---|---|
| Age (y) | 64.52 ± 12.04 | 67.42 ± 13.34 | 63.79 ± 13.17 |
| Male/female | 62/26 | 56/23 | 64/21 |
| Hypertension (%) | 59 (67%) | 62 (78%) | 0 (0) |
| Ischemic stroke (%) | 32 (36%) | 24 (30%) | 0 (0) |
| Diabetes mellitus (%) | 39 (44%) | 30 (38%) | 0 (0) |
| Medication | |||
| Statins, n (%) | 48 (54.5) | 25 (31.6) | 0 (0) |
| ACEI/ARB, n (%) | 63 (71.6) | 51 (64.6) | 0 (0) |
| Beta blockers, n (%) | 58 (65.9) | 42 (53.2) | 0 (0) |
| Aspirin (%) | 60 (68.2) | 26.2 (21.0) | 0 (0) |
| Angiographic analysis | |||
| Maximal stenosis (%) | 89.34 ± 15.62** | 23.87 | - |
| Number of vessel disease | 2.04 ± 0.85 | 1.14 ± 0.93 | - |
| cTnI, ng/L | 19.42 ± 71.19** | 0.03 ± 0.02 | - |
| CK-MB, U/L | 75.42 ± 126.14** | 11.68 ± 4.12 | |
| Gensini score | 62.23 ± 41.58** | 17.20 ± 18.39 | - |
Data are presented as the mean ± SD or number (%) of subjects
Compared with SCAD: * P < 0.05, ** P < 0.01